Key facts
- Japanese pharmaceutical companies are increasing investment in China to access its drug discovery capabilities.
- China's biopharma industry has rapidly advanced, producing groundbreaking drugs and establishing global leaders in contract research.
- U.S. policymakers have expressed concerns, leading to measures like the Biosecure Act to limit Chinese biotech firms' access to U.S. supply chains.
- Takeda's CEO stated Chinese drug development capabilities are approaching U.S. levels.
- Astellas is establishing a new R&D facility in Beijing.
- Both Japan and China have made efforts to align their drug regulations with international standards, including China's accession to the ICH.
Japanese pharmaceutical companies are increasingly directing investment toward China, seeking to leverage the nation's rapidly advancing drug discovery capabilities to identify promising new drug candidates. This strategic pivot reflects China's emergence as a significant player in the global life sciences sector, moving beyond generic drug manufacturing to consistent innovation.
China's biopharmaceutical industry has undergone substantial reforms since 2015, accelerating its regulatory processes and aligning with international standards, including its accession to the International Council for Harmonisation (ICH) in 2017. This rapid development has positioned companies like WuXi AppTec and WuXi Biologics as leaders in global contract drug research and development. Takeda's CEO has noted that Chinese development capabilities are nearing those of the U.S., and Astellas is establishing a new R&D facility in Beijing.
However, China's growing pharmaceutical footprint, particularly its increasing share of U.S. drug imports, has raised national security concerns among U.S. policymakers. Measures such as the Biosecure Act, passed by the House in September 2024, aim to restrict access for top Chinese biotech firms to U.S. supply chains, citing security risks. This geopolitical tension underscores the complex environment in which international drug development collaborations are unfolding.
Efforts to bridge communication and understanding between Japan and China in drug development have been underway, including initiatives like the online media outlet Iyaku Kenpatsu Tatsujin, launched in 2021, which aimed to facilitate information flow between the two industries. The launch of a Chinese edition in February 2025 indicates growing demand from Chinese firms looking to expand internationally.